Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

Penumbra, Inc. (NYSE: PEN), a leader in thrombectomy technology, recently released preliminary financial results for the fourth quarter and full year of 2025, indicating robust growth in its operations. For Q4 2025, the company reported revenues ranging from $383.0 million to $384.8 million, reflecting a year-over-year increase of approximately 21.4% to 22.0% compared to Q4 2024. Notably, excluding the China market's impact, the revenue growth was even more significant, surging between 23.2% and 23.8%.

For the entire year, Penumbra's revenue is anticipated to be between $1,401.3 million and $1,403.1 million, marking a growth rate of about 17.3% to 17.5% over the previous year. When excluding China, the revenue growth for the full year was a substantial 24.7% to 24.9%. The company achieved a gross margin of 67.9% to 68.1% in Q4 and a gross margin of 67.1% for the full year.

Operating income for Q4 is projected between $56.9 million and $60.4 million, resulting in an operating margin of 14.8% to 15.7%. For the full year, income from operations is expected to be between $186.9 million and $190.4 million, constituting an operating margin of approximately 13.3% to 13.6%.

Penumbra continues to innovate in the medical technology space, focusing on critical conditions like ischemic stroke and venous thromboembolism. Through its advanced portfolio, including computer-assisted vacuum thrombectomy (CAVT), the organization aims to enhance patient outcomes across more than 100 countries. For further details, visit their website or their investor relations department.

Penumbra, Inc. has reported impressive preliminary financial results for the fourth quarter and full year of 2025, indicating a strong performance trajectory that could enhance investor confidence. The company achieved fourth-quarter revenues between $383.0 million and $384.8 million, reflecting a growth rate of approximately 21.4% to 22% when compared to the same period in 2024. Notably, excluding the impact from the China region, revenue growth accelerates to an impressive 23.2% to 23.8%—a significant indicator of market success.

For the full year, Penumbra reported revenues between $1,401.3 million and $1,403.1 million, which corresponds to a growth rate of approximately 17.3% to 17.5% year-over-year. Again, when excluding the China market's influence, the growth rate jumps to 24.7% to 24.9%; a clear signal that the firm is establishing a solid foothold outside this challenging market.

The gross margin figures, hovering around 67.9% to 68.1% for Q4, underscore robust cost management practices, while operating margins of 14.8% to 15.7% in the fourth quarter and 13.3% to 13.6% for the full year indicate operational efficiency despite competitive pressures.

Investors should consider these results as clear evidence of Penumbra's strong market position in the thrombectomy industry, coupled with its commitment to innovation in medical technology. The anticipated market growth for the health sector, particularly in thrombectomy devices, suggests that Penumbra may further capitalize on this upward momentum.

However, stakeholders should remain cognizant of global market dynamics, including challenges in specific regions like China. Given the company’s solid fundamentals and growth trajectory, it may be an opportune time for investors to consider positions in Penumbra, Inc., positioning themselves to benefit from future growth in the healthcare technology space.